Key Insights• The Australia biosurgery market represents a mature and sophisticated national market for surgical biomaterials within the Asia-Pacific region. Valued at more than USD 258 million in 2025, the Australian market is underpinned by a universal healthcare system, a well-developed private healthcare sector, and a substantial volume of surgical procedures. The market encompasses a broad range of biologically derived and bio-compatible materials including hemostatic agents, surgical sealants and adhesives, bone-graft substitutes, adhesion barriers, soft-tissue attachments, and staple-line reinforcement products that assist in surgical procedures by controlling bleeding, sealing tissues, promoting regeneration, and preventing postoperative complications.• The Australia biosurgery market is distinguished by its high healthcare expenditure, world-class clinical infrastructure, and the complementary nature of its public and private hospital systems. According to the Australian Institute of Health and Welfare (AIHW), there were 12.8 million hospitalisations in 2024–25, with 60% in public hospitals (7.7 million) and 40% in private hospitals (5.1 million). Healthcare expenditure in Australia reached approximately 10.14% to 10.5% of GDP in 2025. The market is shaped by a complex interplay of demographic trends, technological innovation, regulatory frameworks, and evolving healthcare delivery models, including the rapid adoption of robotic-assisted and minimally invasive surgical techniques.• Healthcare expenditure reached 10.14% to 10.5% of GDP, ranking among the highest globally.

Bone-Graft Substitutes represent the largest product category within the Australian biosurgery market, driven by the high volume of orthopedic procedures. According to the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR), over 100,000 joint replacement procedures are performed annually, with hip and knee arthroplasty representing the highest volumes.• Surgical Sealants and Adhesives represent the fastest-growing product category, driven by increasing adoption of minimally invasive and robotic surgical techniques across Australian hospitals. Australia has performed world-first robotic procedures, including dual robotic system surgeries at St Vincent's Hospital Melbourne.• Australia's aging population represents the most significant long-term demand driver. As of 2025, 18.093% of the population (approximately 4.996 million people) was aged 65 years or older, representing the highest proportion on record. The share of population aged 65 and over rose from 12% to 18% over the past 30 years.The regulatory environment, centered on the Therapeutic Goods Administration (TGA) and the Australian Register of Therapeutic Goods (ARTG), plays a decisive role in shaping market dynamics. The TGA regulates medical devices under the Therapeutic Goods Act 1989 and the Therapeutic Goods (Medical Devices) Regulations 2002.Market Outlook• According to the research report, " Australia Biosurgery Market Overview, 2031 Overview, 2031," published by Actual Market Research, the Australia Biosurgery market was valued at more than USD 258 Million in 2025.• The Australian biosurgery market is expected to maintain steady growth through 2031, supported by favorable demographic trends, ongoing technological innovation, and expanding surgical volumes across both public and private healthcare sectors.

The market's growth trajectory is intrinsically linked to the broader Australian healthcare landscape, including healthcare expenditure, technological adoption, and demographic shifts. Total health expenditure has risen by an estimated 5.2% in 2025-26, reaching $295.3 billion. Health services consume 20% of all government spending, the fourth highest share in the OECD. This substantial healthcare investment provides the financial foundation for sustained surgical activity and biosurgical product utilization.• Technological innovation in biomaterials and surgical delivery systems is expanding the addressable market. Australia has performed world-first robotic procedures, including the first surgery using two separate advanced robotic systems at St Vincent's Hospital Melbourne for breast reconstruction, sarcoma, and head and neck cancer reconstruction surgery. Australia's first public emergency robotic surgery was performed in August 2025.

Buderim Private Hospital became one of the first in the world to provide robotic shoulder replacement surgery. Rising surgical procedures and expanding healthcare access are key drivers propelling market expansion. There were 12.8 million hospitalisations in 2024–25. Private hospitals performed 1,751,384 surgeries in 2024-25. Cataract surgery is performed approximately 250,000 times each year in Australia. The continued expansion of surgical capacity and the adoption of advanced techniques will drive sustained demand for biosurgical products.Market DynamicsDriver: High Surgical Volumes and Aging PopulationAustralia performs millions of surgical procedures annually across its extensive network of public and private hospitals.

There were 12.8 million hospitalisations in 2024–25, with 60% in public hospitals (7.7 million) and 40% in private hospitals (5.1 million). Private hospitals performed 1,751,384 surgeries in 2024-25. Cataract surgery is the most frequently performed procedure, with approximately 250,000 procedures performed each year. According to the AOANJRR, over 100,000 joint replacement procedures are performed annually. The aging population with 18.093% aged 65 and older continues to drive demand for musculoskeletal and ophthalmic interventions. The median age increased from 33.7 years in 1994–95 to 38.4 years in 2024–25.

Healthcare expenditure of 10.14% to 10.5% of GDP provides the financial infrastructure to support expanding surgical volumes.Challenge: Healthcare Spending Pressures and Workforce ConstraintsDespite the market's sophistication, Australia faces persistent challenges that affect the biosurgery market. Healthcare services consume 20% of all government spending, the fourth highest share in the OECD. While total health expenditure continues to rise, reaching $295.3 billion in 2025-26, the health system faces pressures from an aging population and rising healthcare costs. The private hospital sector has experienced consolidation, with 633 private hospitals in 2025 (down from 641 in 2020), with 82 hospitals closing over that period. Workforce constraints also pose challenges as of 2023, there were only 1,004 ophthalmologists practicing in Australia, with only seven in the vast Northern Territory. Additionally, the number of practicing physicians decreased by 4.7% year-on-year in South Korea (a comparable market), and similar workforce pressures exist in Australia, potentially limiting surgical volume growth.Trend: Accelerating Adoption of Robotic-Assisted and Minimally Invasive SurgeryThe Australian biosurgery market is experiencing a significant trend toward robotic-assisted and minimally invasive surgical techniques.

Australia has performed world-first procedures, including the first surgery using two separate advanced robotic systems at St Vincent's Hospital Melbourne. Australia's first public emergency robotic surgery was successfully performed in August 2025. Buderim Private Hospital became one of the first in the world to provide robotic shoulder replacement surgery, and only the second in Australia to perform total shoulder replacement surgery assisted by the Mako robot. Gynaecologists have performed v-NOTES surgery, allowing entry through the vagina to remove the uterus, cervix, and fallopian tubes a procedure that is about 40 minutes less time-consuming than a traditional hysterectomy. This shift toward advanced surgical platforms creates new opportunities for biosurgical products specifically designed for minimally invasive and robotic applications. Surgical sealants and adhesives that can be delivered through small incisions, hemostatic agents optimized for sprayable application, and staple-line reinforcement products compatible with robotic staplers are increasingly in demand.Policies• The Therapeutic Goods Administration (TGA) serves as the primary regulatory authority for medical devices in Australia.

The TGA regulates medical devices under the Therapeutic Goods Act 1989. Most medical devices must be included in the Australian Register of Therapeutic Goods (ARTG) before they can be supplied in Australia.• The Therapeutic Goods (Medical Devices) Regulations 2002 establish the Essential Principles for safety and performance of medical devices. Importing, supplying, or exporting a medical device that does not meet the Principles is an offence under the Therapeutic Goods Act 1989.• Medical devices are classified into classes based on risk, with Class III and Class IIb devices subject to the most rigorous requirements. Sponsors of Class III and Class IIb medical devices are expected to meet the TGA's new requirements by July 2026.• Unique Device Identification (UDI) requirements are being phased in. Class III devices must comply with UDI requirements, with deadlines extending to July 2026 for Class III and Class IIb devices.• The Australian Register of Therapeutic Goods (ARTG) serves as the central database for all medical devices approved for supply in Australia. Manufacturers and sponsors must include their medical devices in the ARTG before they can be supplied in Australia.• Private health insurance in Australia complements the public Medicare system, with private hospitals accounting for 40% of all hospital admissions and performing 1,751,384 surgeries in 2024-25.

The private hospital sector plays a crucial role in surgical care delivery.Segment AnalysisAustralia Biosurgery Market By Product• Bone-Graft Substitutes represent the largest product category within the Australian biosurgery market, driven by the high volume of orthopedic and spinal procedures. According to the AOANJRR, over 100,000 joint replacement procedures are performed annually. These products include demineralized bone matrix (DBM), synthetic bone grafts, and biologic grafts incorporating growth factors. The aging Australian population with 18.093% aged 65 and older continues to drive demand for musculoskeletal interventions requiring bone-graft substitutes. The MBS includes items for bone grafting procedures, including maxillary sinus bone grafts.• Hemostatic Agents constitute a major market segment, reflecting their essential role across all surgical disciplines. These products including topical hemostats, flowable matrices, fibrin sealants, and thrombin-based agents are utilized in virtually every surgical procedure to control intraoperative bleeding.

With 12.8 million hospitalisations in 2024–25, demand for hemostatic products is substantial and growing. Private hospitals performed 1,751,384 surgeries in 2024-25.• Surgical Sealants and Adhesives represent the fastest-growing product category in the Australian biosurgery market, driven by increasing adoption of minimally invasive and robotic surgical techniques. These products including fibrin sealants, synthetic polymer-based sealants, and protein-based adhesives are used to seal tissue surfaces, prevent fluid and air leaks, and reinforce surgical anastomoses. The rapid adoption of robotic surgery, including dual robotic system procedures and public emergency robotic surgeries, supports the expansion of this segment.• Adhesion Barriers represent a clinically important product category used to prevent postoperative adhesion formation in abdominal, pelvic, and gynecological surgeries. The category continues to benefit from ongoing product innovation and clinical evidence supporting adhesion prevention, particularly as the volume of gynecological and abdominal procedures remains substantial. The adoption of v-NOTES surgery for hysterectomy represents a significant advancement in gynecological surgery.• Soft-Tissue Attachments encompass products used to reinforce, repair, or secure soft tissues, including surgical meshes, biologic scaffolds, and tissue grafts.

These products are utilized in hernia repair, pelvic floor reconstruction, and various other soft-tissue procedures. The NSW Health system has established same-day surgery targets for inguinal hernia repair (90% by 2025-26) and elective cholecystectomy (75% by 2025-26), reflecting the high volume of these procedures.• Staple-Line Reinforcement products are utilized in gastrointestinal, bariatric, and thoracic procedures to strengthen tissue interfaces along surgical staple lines, reducing the risk of bleeding and leakage. The increasing volume of thoracic and gastrointestinal procedures supports steady demand for these products.Australia Biosurgery Market By Application• Orthopedic Surgery is the largest application area for biosurgical products in Australia, driven by the high volume of joint replacement, trauma, and spinal procedures. According to the AOANJRR, over 100,000 joint replacement procedures are performed annually. The aging population with 18.093% aged 65 and older continues to drive demand for musculoskeletal interventions. Robotic shoulder replacement surgery has been introduced, and the Mako robot is being used for hip and shoulder replacements.• General Surgery encompasses a broad range of abdominal, gastrointestinal, and soft-tissue procedures, including inguinal hernia repair, cholecystectomy, and colorectal surgery.

NSW Health has established same-day surgery targets: 90% for inguinal hernia repair and 75% for elective cholecystectomy by 2025-26. Biosurgical products utilized include hemostatic agents, surgical sealants, staple-line reinforcement products, and adhesion barriers.• Cardiovascular Surgery represents the fastest-growing application area in the Australian biosurgery market, driven by the high prevalence of cardiovascular disease in the aging population. Vascular sealants, hemostatic agents, and soft-tissue attachments are increasingly utilized in cardiac and vascular procedures. The adoption of robotic-assisted cardiovascular procedures is expanding.• Neurological Surgery utilizes biosurgical products particularly hemostatic agents and dural sealants to manage bleeding and prevent cerebrospinal fluid leaks in cranial and spinal procedures. The aging population and increasing incidence of neurological conditions drive demand in this specialty. Robotic systems are being used for sarcoma and head and neck cancer reconstruction surgery.• Reconstructive Surgery involves the use of biosurgical products to restore, repair, or reconstruct damaged or surgically altered tissues, including soft-tissue repair, tissue reinforcement, and wound reconstruction following injury, disease, or surgery.

Robotic systems are being used for breast reconstruction.• Gynecological Surgery includes biosurgical applications in procedures involving the female reproductive system, with products used for hemostasis, tissue sealing, adhesion prevention, tissue repair, and reinforcement. The adoption of v-NOTES surgery for hysterectomy represents a significant advancement.• Urological Surgery covers biosurgical applications in procedures involving the urinary tract and male reproductive system, with products used for bleeding control, tissue sealing, reinforcement, repair, and prevention of postoperative complications.• Thoracic and Other Surgeries represent a growing application area, driven by increasing adoption of video-assisted thoracoscopic surgery (VATS) and the rising burden of lung cancer and other thoracic conditions.Australia Biosurgery Market By Source/Origin• Biologic products represent the largest source category in the Australian biosurgery market, driven by their superior biocompatibility and natural healing properties. These products include demineralized bone matrix, fibrin sealants, collagen hemostats, allografts, and xenografts. The TGA's rigorous requirements for biological materials ensure high safety standards and support market confidence.• Synthetic and Semi-Synthetic products represent the fastest-growing source category in the Australian market, driven by cost-effectiveness, consistent quality, lower immunogenicity risks, and longer shelf life. These products include synthetic bone substitutes, PEG-based sealants, synthetic meshes, and polysaccharide hemostats. The Australian healthcare system's emphasis on cost-effectiveness favors synthetic alternatives for certain applications.Australia Biosurgery Market By End-User• Hospitals remain the largest end-user segment for biosurgical products in Australia, accounting for the majority of revenue.

There are over 1,300 hospitals in Australia, both public and private. There were 12.8 million hospitalisations in 2024–25, with 60% in public hospitals (7.7 million) and 40% in private hospitals (5.1 million). Private hospitals performed 1,751,384 surgeries in 2024-25. The concentration of complex surgical procedures and availability of specialized surgical teams make hospitals the primary setting for biosurgical product utilization.• Ambulatory Surgical Centers (ASCs) represent the fastest-growing end-user segment in the Australian biosurgery market, driven by the broader healthcare industry shift toward outpatient and same-day discharge models. Same-day hospitalisations increased by 1.9% (8.0 million to 8.2 million) in 2024–25. Same-day separations as a percentage of total admissions for private hospitals amount to 74.1%.

The expansion of day surgeries supports the adoption of biosurgical products in these settings.• Clinics represent a growing end-user segment, with specialty clinics performing eligible surgical or minimally invasive procedures utilizing biosurgical products for tissue repair, bleeding control, and sealing.Australia Biosurgery Market Economics• Australia’s biosurgery market benefits from a dual healthcare system comprising public Medicare and private health insurance. Healthcare expenditure reached approximately 10.14–10.5% of GDP, with total health expenditure projected at $295.3 billion in 2025–26. Public hospital tenders, private hospital agreements, and surgeon preferences shape procurement. Private hospitals account for around 40–41% of hospital admissions, making both public and private reimbursement pathways important for manufacturers.• Australia has an extensive healthcare infrastructure, with more than 1,300 hospitals, including 633 private hospitals, and 12.8 million hospitalisations in 2024–25. A highly trained surgical workforce supports the adoption of advanced biosurgical technologies, although regional workforce distribution remains a challenge. Continued investment in hospitals, day surgeries, and specialist services is expected to increase surgical procedure volumes and demand for biosurgical products.• Innovation and technology adoption are key market drivers.

Australian hospitals are increasingly adopting robotic-assisted surgery, minimally invasive procedures, and advanced biomaterials, including world-first robotic procedures. The Therapeutic Goods Administration (TGA) provides a rigorous regulatory framework under the Therapeutic Goods Act 1989, with medical devices classified according to risk. Compliance with evolving requirements and registration through the Australian Register of Therapeutic Goods (ARTG) are essential for market access.• The long-term outlook remains positive, supported by population ageing, technological innovation, and strong healthcare infrastructure. Around 18.1% of Australia’s population is aged 65 or older, with this share expected to increase to approximately 7.75 million people by 2050. The Australian biosurgery market was valued at more than USD 258 million in 2025. Manufacturers that effectively manage reimbursement, regulation, procurement, and innovation can capture significant opportunities in this strategically important market.Considered in this report• Historic Year: 2020• Base year: 2025• Estimated year: 2026• Forecast year: 2031Aspects covered in this report• Biosurgery Market with its value and forecast along with its segments• Various drivers and challenges• On-going trends and developments• Top profiled companies• Strategic recommendationBy Product• Bone-Graft Substitutes• Hemostatic Agents• Surgical Sealants & Adhesives• Adhesion Barriers• Soft-Tissue Attachments• Staple-Line ReinforcementBy Application:• Orthopedic Surgery • General Surgery • Neurological Surgery • Cardiovascular Surgery • Reconstructive Surgery • Gynecological Surgery • Urological Surgery • Other surgeries (Thoracic surgeries & more)By Source/Origin• Biologic• Synthetic / Semi-syntheticBy End-user:• Hospitals • Ambulatory Surgical Centers • Clinics • Others.